
|Videos|January 31, 2019
Real-World Management of Patients with BRAF-V600E mCRC
Advertisement
Scott Kopetz, MD, PhD, FACP, provides advice on the management of patients with BRAFV600E-mutant metastatic colorectal cancer with the triplet regimen of encorafenib, binimetinib, and cetuximab, a regimen studied in the BEACON and ANCHOR trials.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
3
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5



































